glp 1 gip triple agonist LY3437943, a novel glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Demonstrated metabolic effects of GIP,

Change in GCL was neither associated with the treatment group nor with GCL volume at baseline (Supplementary Table 4)

Further, despite internal resistance at Novo, Knudsen initiated trials administering a higher dose of liraglutide (Saxenda) for the treatment of obesity

Most intestinal K cells secrete a biologically active form of GIP consisting of 42 amino acids, GIP (142), which is derived from a 153 amino acid preprohormone precursor distinct from preproglucagon (14)

To mitigate these risks, professional societies recommend discontinuing once-weekly GLP-1RAs at least one week prior to surgery

Christensen, M., Vedtofte, L., Holst, J

Tirzepatide may have broader anti-inflammatory mechanisms